Pharma News, Research & Solutions CSR News

"AIDS Won't Stop for COVID-19": Meet 3 Inspiring Women Who Are as Committed as Ever to Making HIV History

Summary: 

As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.

Blog

As the International Aids Society Conference kicks off virtually this year, we sat down with three attendees, including activist and actress Laverne Cox, to talk about their groundbreaking work with HIV/AIDS in the midst of a global pandemic.

Increasing Diversity in Clinical Trials: A Collaboration with Tufts Center for the Study of Drug Development

Article

To effectively support the goal of access for all citizens, we must consider all citizens. But delivering on that goal takes a commitment to understanding deeply who patients are, their needs, and how we can best support positive health outcomes. We need to start at the beginning and build into every decision we make and step we take the diverse socio economic and individual health considerations of each person we encounter.

#BacktheFrontline: Joe Wolk, Executive Vice President, Chief Financial Officer, Johnson & Johnson

Multimedia with summary

Accelerated innovation. Resources in the hands of health workers. Profit returned to the frontline.

Learn more about how we #BackTheFrontline by investing in innovators developing scalable solutions to COVID-19 from Johnson & Johnson Impact Ventures Chair Joe Wolk.

Follow along with us on @JNJGlobalHealth on Twitter and/or Instagram to hear from our leaders, employees and partners around the world about how YOU can meaningfully contribute.

Johnson & Johnson Announces European Commission Approval for Janssen's Preventive Ebola Vaccine

Summary: 
This marks the first major regulatory approval of a vaccine developed by Janssen

 

The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology

 

Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19
Press Release
This marks the first major regulatory approval of a vaccine developed by Janssen

 

The Ebola vaccine regimen leverages Janssen’s AdVac® technology, plus Bavarian Nordic’s established MVA-BN® technology

 

Janssen’s AdVac® technology is also being used to develop a vaccine candidate to prevent COVID-19

Alexion Charitable Foundation Announces First Rare Belonging® Grants

Funding supports efforts by National Organization for Rare Disorders (NORDⓇ) and Global Genes to address needs of the rare disease community arising from COVID-19 pandemic
Press Release

BOSTON, June 24, 2020 /3BL Media/ -- The Alexion Charitable Foundation, launched by Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in February 2020, has announced it has awarded a total of $1.1 million in initial grants that align with its Rare Belonging® focus. Rare Belonging seeks to advance emotional well-being and educational opportunities, and provide relief for critical needs, for those living with or affected by a rare disease.

The Hidden Face of MS

Article

Imagine spending years feeling isolated and alone as you navigate a long winding road to diagnosis, searching for answers.  You finally hear the words “multiple sclerosis” (MS) and although shocking, you feel some sense of relief to have an answer. But as you search for stories of others who have walked this same path, the faces staring back at you are nothing like your own. Once again, you feel isolated and alone, this time with the shame of feeling different.

An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences

Blog

After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently given to patients intravenously through daily infusions in the hospital.

Cancer Immunotherapy Awareness Month™ at Alkermes

Multimedia with summary

Along with the Society for Immunotherapy of Cancer we strive for a future #Immune2Cancer because to our team, cancer immunotherapy research is personal. Our scientists are researching potential, new cancer treatment options for our loved ones and yours.

About Alkermes

Merck Named to 100 Best Corporate Citizens of 2020

Company is ranked No. 1 in industry on the 2020 100 Best Corporate Citizens list
Press Release

3BL Media has named Merck to its annual 100 Best Corporate Citizens ranking, recognizing outstanding environmental, social and governance (ESG) transparency and performance among the 1,000 largest, U.S. public companies.

COVID-19's Unequal Toll on Communities of Color

by Michael Sneed, Chief Communication Officer, Johnson & Johnson
Blog

Tomorrow I will have the distinct honor of participating in a panel discussion held by the Congressional Black Caucus Foundation, titled Black America – The Double Pandemic, where I will join experts examining the incredibly damaging impact of the COVID-19 pandemic on the Black community. 

Pages

Subscribe to Pharma News, Research & Solutions